Fluticasone (Flovent)

Fluticasone, widely known by the brand name Flovent, is the most commonly prescribed inhaled corticosteroid for the treatment of feline asthma and other inflammatory airway diseases in cats. This medication has become the gold standard for maintenance therapy of feline respiratory conditions, offering effective control of airway inflammation through a delivery system that minimizes systemic drug exposure and associated side effects. Fluticasone propionate is a synthetic corticosteroid with high topical anti-inflammatory potency, making it highly effective when delivered directly to the airways while producing minimal effects elsewhere in the body. Its widespread use in both human and veterinary medicine has established a robust track record of safety and efficacy.

The mechanism of action of fluticasone involves comprehensive suppression of the inflammatory processes that drive feline asthma and related conditions. When inhaled and deposited on airway surfaces, fluticasone enters cells and binds to glucocorticoid receptors, initiating a cascade of anti-inflammatory effects. The medication inhibits the production of inflammatory cytokines, reduces the release of inflammatory mediators from mast cells and other immune cells, decreases mucus secretion from airway goblet cells, and prevents the recruitment of eosinophils and other inflammatory cells to the airways. Over time, these effects reduce airway inflammation, decrease bronchial hyperreactivity, and can help reverse some airway remodeling that occurs with chronic asthma. The benefits of inhaled fluticasone build gradually over days to weeks of consistent use.

Fluticasone is administered to cats using a metered-dose inhaler in conjunction with a feline-specific aerosol chamber, most commonly the AeroKat device. The chamber serves as a holding reservoir for the medication aerosol and includes a face mask sized to fit over a cat's nose and mouth. When the inhaler is actuated into the chamber, the medication forms a fine aerosol that the cat can then inhale over several normal breaths. This system overcomes the fundamental challenge that cats cannot coordinate their breathing with inhaler actuation as humans do. Flovent is available in multiple strengths, allowing veterinarians to select the appropriate dose for each patient and adjust therapy based on response.

The safety profile of inhaled fluticasone is excellent compared to systemic corticosteroids, with minimal drug absorption beyond the airways limiting the potential for steroid side effects. Cats on long-term inhaled fluticasone therapy avoid the significant side effects associated with oral prednisolone, including polyuria, polydipsia, polyphagia, weight gain, diabetes mellitus risk, and immunosuppression. This favorable safety profile makes fluticasone ideal for lifelong asthma management, as many asthmatic cats require ongoing therapy. Veterinary supervision throughout treatment remains important to ensure proper administration technique, assess treatment response, and monitor for any adverse effects that may occur despite the medication's localized action.

The primary indication for fluticasone in cats is the long-term maintenance treatment of feline asthma, a chronic inflammatory airway disease that affects an estimated one to five percent of the cat population. Feline asthma is characterized by eosinophilic infiltration and inflammation of the lower airways, bronchospasm, excessive mucus production, and progressive airway remodeling if inadequately controlled. Cats with asthma experience symptoms including chronic coughing, wheezing, labored breathing, and acute respiratory distress during severe attacks. Fluticasone addresses the fundamental inflammatory pathology underlying asthma, reducing airway inflammation to prevent symptoms and protect against long-term airway damage. This preventive approach distinguishes maintenance therapy from rescue treatment of acute symptoms.

As a maintenance medication, fluticasone is administered regularly regardless of current symptoms to achieve and maintain control of airway inflammation. Consistent daily use allows the anti-inflammatory effects to build over time, progressively reducing airway reactivity and the frequency and severity of asthma attacks. Most cats show meaningful improvement within one to two weeks of starting therapy, with full benefits often achieved by four to six weeks of consistent treatment. Fluticasone does not provide immediate bronchodilation for acute attacks, so cats with asthma typically also have access to rescue bronchodilator medications for breakthrough symptoms. The goal of maintenance fluticasone therapy is to minimize the need for rescue medication.

Chronic bronchitis in cats represents another important application for inhaled fluticasone therapy. While distinct from allergic asthma in its pathophysiology, chronic bronchitis involves persistent airway inflammation that responds to corticosteroid treatment. The condition manifests with chronic coughing, mucus accumulation, and progressive respiratory compromise. Inhaled fluticasone can reduce bronchial inflammation, decrease mucus production, and improve respiratory function in affected cats. Treatment protocols may resemble those for asthma, with regular maintenance therapy aimed at controlling symptoms and preventing disease progression. Fluticasone may be used alone or combined with bronchodilators depending on disease severity.

Fluticasone serves as an important alternative to systemic corticosteroids for cats requiring long-term anti-inflammatory therapy. Many cats with asthma were traditionally managed with oral prednisolone, which effectively controls airway inflammation but produces significant systemic effects with prolonged use. Transitioning from oral steroids to inhaled fluticasone allows maintained disease control while eliminating or substantially reducing systemic corticosteroid exposure. This transition is particularly valuable for cats experiencing steroid side effects, diabetic cats whose glucose control is complicated by steroids, and cats requiring lifelong therapy. The transition typically occurs gradually under veterinary supervision.

The selection of fluticasone among available respiratory medications reflects its established position as the first-choice inhaled corticosteroid in feline practice. Extensive veterinary experience with fluticasone provides confidence in its safety and efficacy. The availability of multiple strengths allows tailored dosing from low maintenance doses to higher doses for more severe disease. Fluticasone's high topical potency with low systemic bioavailability makes it particularly suitable for localized airway treatment. For cats that do not respond adequately to fluticasone or experience local side effects, other inhaled corticosteroids such as budesonide or beclomethasone provide alternative options.

Fluticasone dosing in cats is determined by the veterinarian based on the severity of respiratory disease, the specific product strength selected, and the individual patient's response to therapy. Unlike many medications dosed by body weight, inhaled fluticasone is typically prescribed as a specific number of actuations from a particular inhaler strength, given once or twice daily. Available strengths of Flovent include 44, 110, and 220 micrograms per actuation, allowing veterinarians to select an appropriate dose for each cat's needs. Initial dosing depends on disease severity, with higher doses often used for cats with significant symptoms and lower maintenance doses for cats with mild or well-controlled disease.

Administration of fluticasone requires a feline-specific aerosol chamber device, with the AeroKat being the most widely used system in veterinary practice. The chamber consists of a cylindrical holding reservoir with a one-way valve and an attached face mask designed to fit cat facial anatomy. To administer medication, the owner shakes the Flovent inhaler, attaches it to the chamber, and actuates one puff into the chamber. The mask is then gently but firmly placed over the cat's nose and mouth, creating a seal. The cat breathes normally through the mask for seven to ten breaths, inhaling the medication from the chamber. If multiple puffs are prescribed, the process is repeated for each actuation.

Successful long-term inhaled therapy requires training the cat to accept the aerosol chamber and mask, which typically takes one to three weeks of patient conditioning. The training process involves gradual desensitization, introducing the chamber components slowly while providing positive reinforcement with treats or affection. Initially, the cat simply investigates the equipment without any pressure. Subsequent sessions involve touching the mask to the face briefly, then holding it in place for increasing durations. The sound of the inhaler can be introduced separately. Eventually, medication delivery begins. Rushing this process often results in ongoing resistance, while patient training produces cats that tolerate treatments calmly for years.

The duration of fluticasone therapy depends on the underlying condition and individual patient factors. Feline asthma is a chronic condition, and most asthmatic cats require ongoing maintenance therapy to maintain disease control. Many cats continue fluticasone treatment for life, with periodic veterinary evaluation to assess disease status and optimize dosing. Once good control is achieved, some cats can be maintained on lower doses or less frequent administration. Attempts at dose reduction are made gradually under veterinary supervision. Seasonal variations in symptoms may influence treatment intensity for some cats, with higher doses during problem seasons.

If a dose of fluticasone is missed, it should be given as soon as remembered, with the regular schedule then resumed. Since fluticasone works through gradual anti-inflammatory effects rather than providing immediate symptom relief, missing occasional doses typically does not cause acute problems. However, consistent administration provides optimal disease control, and frequent missed doses may result in breakthrough symptoms or loss of disease control. Establishing a daily routine that incorporates medication administration helps prevent forgotten doses. If the cat's symptoms worsen after missed doses, the veterinarian should be consulted.

Regular veterinary follow-up is essential for cats receiving inhaled fluticasone therapy. Follow-up visits assess disease control, evaluate for any adverse effects, ensure proper administration technique, and determine if dose adjustments are needed. The veterinarian may assess respiratory status through physical examination, discussion of symptom frequency and severity, and sometimes chest radiographs. Treatment modifications are made based on clinical response, with the goal of achieving optimal disease control using the lowest effective fluticasone dose. Most cats require ongoing therapy, and annual or biannual evaluations help maintain appropriate management.

Inhaled fluticasone has an excellent safety profile compared to systemic corticosteroids, making it suitable for long-term use in cats with chronic respiratory conditions. The medication acts primarily in the airways with minimal absorption into the systemic circulation, substantially reducing the risk of typical corticosteroid side effects. Most cats tolerate fluticasone therapy very well when administered properly. However, adverse effects can occur, and pet owners should be aware of what to monitor during treatment. Understanding potential side effects allows for prompt recognition and appropriate veterinary consultation when needed.

Local side effects affecting the mouth and throat represent the most commonly observed adverse reactions to inhaled fluticasone. Oropharyngeal candidiasis, commonly known as thrush, is a fungal infection that can develop due to corticosteroid-induced local immunosuppression in the oral cavity. Signs may include reluctance to eat, drooling, bad breath, or visible white patches in the mouth. Upper respiratory symptoms such as sneezing, nasal discharge, or voice changes can occasionally occur. Proper administration technique that maximizes medication delivery to the lower airways reduces oral deposition and associated complications. Wiping the cat's face and around the mouth after treatment may also help. If thrush develops, antifungal treatment is typically effective.

Systemic corticosteroid effects are uncommon with appropriately dosed inhaled fluticasone but can occur, particularly at higher doses or with prolonged use. Possible effects include increased thirst and urination, increased appetite, weight changes, and skin or coat changes. These effects are typically much milder than those seen with oral prednisolone. Adrenal suppression, where the body's natural cortisol production decreases due to exogenous corticosteroid exposure, is theoretically possible with long-term high-dose therapy. Regular veterinary monitoring helps identify any emerging systemic effects. If significant systemic signs develop, dose reduction or alternative approaches may be considered.

Behavioral changes have been reported occasionally in cats receiving corticosteroid therapy, though these are more commonly associated with systemic administration. Possible changes include lethargy, decreased activity, or alterations in normal behavior patterns. Since these changes can be subtle and develop gradually, owners should pay attention to their cat's overall demeanor. Distinguishing medication effects from changes related to the underlying respiratory condition or other factors can be challenging. If significant behavioral changes occur, veterinary evaluation helps determine the cause and whether treatment modifications are warranted.

Long-term considerations for cats on chronic fluticasone therapy include monitoring for any cumulative effects and ensuring continued disease control with the minimum necessary dose. Some cats may be able to have their dose reduced after achieving stable disease control, while others require consistent maintenance therapy. Periodic attempts at dose reduction, conducted under veterinary supervision, help identify the lowest effective dose for each individual. Regular follow-up allows the veterinarian to assess ongoing response to therapy, identify any emerging problems, and optimize the treatment plan. The excellent safety profile of inhaled fluticasone makes it appropriate for lifelong use when needed to control chronic respiratory disease.

Fluticasone is contraindicated in cats with known hypersensitivity or allergy to fluticasone or other corticosteroid medications. True allergic reactions to corticosteroids are rare, but cats that have experienced adverse reactions to any corticosteroid should have this history carefully evaluated before prescribing inhaled fluticasone. Cross-reactivity between different corticosteroid medications is possible. Signs of hypersensitivity may include worsening respiratory symptoms, facial swelling, hives, or other allergic manifestations. Any history of corticosteroid reactions should be documented in the cat's medical record and communicated to all veterinary care providers involved in the cat's treatment.

Active respiratory infections represent a significant precaution for inhaled fluticasone use. Corticosteroids have immunosuppressive effects that can impair the body's ability to fight infections. Cats with active bacterial, viral, or fungal respiratory infections may experience worsening of their infection if corticosteroid therapy is initiated or continued. Treatment of the underlying infection should generally be completed or well underway before starting inhaled fluticasone therapy. In some situations, such as cats with concurrent asthma and infection, antibiotics or antifungal medications may be prescribed alongside inhaled steroids, but this requires careful veterinary judgment regarding the balance of risks and benefits.

Certain systemic health conditions warrant careful consideration when prescribing inhaled fluticasone. While inhaled delivery minimizes systemic absorption, some medication does reach the bloodstream, and effects on other organ systems remain possible, particularly at higher doses. Cats with diabetes mellitus should be monitored for effects on glucose control, though these are typically much less significant than with oral corticosteroids. Cats with known or suspected infections elsewhere in the body may be at risk for infection worsening. Immunocompromised cats require particularly careful consideration of the risks and benefits of corticosteroid therapy. The veterinarian evaluates each cat's complete health status when determining the appropriateness of fluticasone treatment.

Pregnancy, nursing, and pediatric use present additional considerations for inhaled fluticasone therapy. The safety of inhaled corticosteroids during feline pregnancy has not been thoroughly established, and potential effects on fetal development must be weighed against the risks of uncontrolled maternal respiratory disease. Use during pregnancy should be limited to situations where benefits clearly outweigh potential risks. Nursing queens present similar concerns due to potential, though likely minimal, transfer of medication to kittens. Very young kittens may have difficulty tolerating the aerosol chamber and mask, and their developing organ systems may respond differently to corticosteroid exposure. Veterinary guidance is essential for these special populations.

Comprehensive disclosure of all medications, supplements, and treatments a cat is receiving is essential before starting inhaled fluticasone therapy. While inhaled corticosteroids have fewer systemic drug interactions than oral steroids due to their localized action and limited systemic absorption, potential interactions still exist. The veterinarian needs complete information about the cat's medication regimen to ensure safe and effective therapy. Even supplements and over-the-counter products should be disclosed, as they may affect treatment in unexpected ways.

Concurrent use of systemic corticosteroids with inhaled fluticasone requires careful coordination. Cats transitioning from oral prednisolone to inhaled fluticasone typically undergo a gradual tapering process, with the systemic steroid dose slowly reduced as inhaled therapy takes effect. During this transition, the total corticosteroid exposure from both routes must be considered. Using both systemic and inhaled corticosteroids at full doses simultaneously increases the risk of corticosteroid side effects. The veterinarian plans the transition to maintain respiratory control while progressively reducing systemic steroid exposure. Most cats can eventually be maintained on inhaled therapy alone.

Medications that affect immune function may have additive effects when combined with inhaled fluticasone. Other immunosuppressive drugs, while uncommonly prescribed in cats, combined with corticosteroids may further impair immune responses and increase infection susceptibility. Cats receiving any immune-modulating therapy require careful monitoring. Some medications may affect corticosteroid metabolism, though this is primarily a concern for systemically absorbed drugs. The veterinarian considers all concurrent medications when developing treatment plans and monitoring protocols for cats receiving inhaled fluticasone.

Bronchodilator medications are frequently used in combination with inhaled fluticasone for comprehensive asthma management, and this combination is safe and often more effective than either medication alone. Albuterol, delivered via metered-dose inhaler through an aerosol chamber, serves as a rescue bronchodilator for acute symptoms. Oral bronchodilators such as terbutaline or theophylline may be used for cats requiring additional bronchodilation beyond inhaled therapy. The combination addresses both the inflammatory and bronchospastic components of asthma. Some protocols recommend administering the bronchodilator before fluticasone to open airways and potentially improve corticosteroid deposition, though specific administration sequences should follow veterinary guidance.

General precautions for inhaled fluticasone therapy emphasize proper administration technique, consistent use, and appropriate veterinary monitoring. Effective treatment depends on adequate delivery of medication to the lower airways, which requires correct use of the aerosol chamber and face mask. The mask must create a proper seal over the nose and mouth, and the cat must take sufficient breaths through the chamber. Poor technique can result in inadequate disease control or increased local side effects from oral deposition. Pet owners should receive thorough training in administration and have the opportunity to demonstrate proper technique under supervision.

Breed-specific considerations for inhaled fluticasone relate primarily to respiratory anatomy and predisposition to certain health conditions. Brachycephalic breeds such as Persians, Himalayans, and Exotic Shorthairs have shortened facial structures that can complicate aerosol chamber use. Standard face masks may not fit properly over their flat faces, potentially requiring specialized sizing. These breeds may also have complex respiratory conditions beyond simple asthma, requiring thorough diagnostic evaluation to ensure inhaled corticosteroid therapy is appropriate. Siamese and Oriental breeds, which have higher asthma prevalence, are frequent candidates for fluticasone therapy but do not appear to have unusual sensitivities to the medication itself.

Proper handling and maintenance of the inhaler and aerosol chamber ensures consistent medication delivery. The Flovent inhaler should be shaken before each use and primed according to manufacturer instructions when new or after periods of non-use. Keeping track of doses used ensures replacement before the inhaler is empty. The aerosol chamber should be cleaned regularly with mild dish soap and allowed to air dry without rinsing, which leaves a thin soap film that reduces static electricity and improves medication delivery. The face mask should be inspected for cracks or damage. Chambers should be replaced according to manufacturer recommendations, typically annually.

Monitoring during fluticasone therapy involves assessment of both treatment effectiveness and potential adverse effects. Signs of good asthma control include reduced coughing frequency and severity, normal breathing effort, good activity levels, and decreased need for rescue bronchodilator medications. Pet owners should track symptoms and medication use between veterinary visits. Warning signs that may indicate inadequate control or adverse effects include persistent respiratory symptoms, worsening coughing, development of oral lesions, or any significant changes in behavior or general health. Regular veterinary evaluation allows for treatment optimization based on individual response.

Special populations requiring additional precautions include geriatric cats, very young kittens, and cats with concurrent health conditions. Older cats may have multiple health issues that influence respiratory treatment decisions, including conditions that could be affected by any systemic corticosteroid exposure. Geriatric cats may also have reduced tolerance for the stress of aerosol chamber administration. Kittens require careful attention to mask sizing and may need modified conditioning approaches. Cats with diabetes, immunocompromise, or other chronic conditions require individualized treatment plans that account for all their health needs. Close communication between pet owners and veterinarians helps optimize care for these complex patients.

Proper storage of the fluticasone metered-dose inhaler ensures the medication remains effective and delivers accurate doses throughout its use period. The Flovent inhaler should be stored at room temperature, typically between 68 and 77 degrees Fahrenheit. Exposure to extreme heat above 120 degrees Fahrenheit can cause pressure buildup in the pressurized canister and should be avoided. The inhaler should not be stored in direct sunlight, near heat sources, or in vehicles during hot weather. Freezing should also be avoided, as extreme cold can affect the propellant and medication delivery. The protective cap should remain on the mouthpiece when the inhaler is not in use to prevent contamination and protect the valve.

The metered-dose inhaler requires specific handling practices for optimal performance and accurate dosing. Before each use, the canister should be shaken well for several seconds to ensure proper mixing of the medication suspension with the propellant. New inhalers should be primed by releasing several test sprays away from the face before first use, with the exact number of priming actuations specified in the product instructions. Re-priming is typically needed if the inhaler has not been used for several days or if it has been dropped. The inhaler should be held upright with the mouthpiece at the bottom during actuation. Tracking the number of doses used ensures timely replacement before the canister is empty.

The aerosol chamber requires regular care and maintenance to function effectively. Periodic cleaning involves disassembling the chamber, washing all parts in warm water with mild dish soap, and allowing them to air dry completely without rinsing or towel drying. This air drying technique leaves a thin soap film on the interior surfaces that reduces static electricity, preventing medication particles from sticking to the chamber walls instead of being inhaled by the cat. The face mask should be inspected regularly for cracks, tears, or deterioration that could affect the seal. Chambers should be replaced according to manufacturer guidelines, typically every six to twelve months, as plastic materials can degrade over time and affect performance.

Safe handling and disposal practices protect household members and the environment. The Flovent inhaler and aerosol chamber should be stored in a secure location out of reach of children and other pets. While the medication doses are small, preventing accidental exposure is important. Pet owners should wash their hands after handling the inhaler. Used or expired inhalers are pressurized containers and should not be punctured or incinerated. Proper disposal should follow local pharmaceutical disposal guidelines or utilize veterinary take-back programs or pharmacy disposal services when available. Medications should not be flushed down drains or toilets due to environmental concerns.

Inhaled fluticasone is effective across all cat breeds for managing respiratory inflammation when administered properly with appropriate technique. There are no documented breed-specific sensitivities to fluticasone, but certain breeds have anatomical features or health predispositions that influence how therapy is approached. Understanding these breed-related factors helps veterinarians optimize fluticasone treatment for individual cats while addressing potential challenges specific to certain breeds.

Siamese and Oriental breed cats have an increased prevalence of feline asthma compared to other breeds, making them the most frequent candidates for inhaled fluticasone therapy. Studies suggest Siamese cats may be significantly overrepresented among cats diagnosed with asthma, potentially due to genetic factors affecting airway reactivity or immune responses. Despite this increased likelihood of needing inhaled corticosteroid therapy, Siamese cats do not appear to have unusual responses to fluticasone itself. Owners of Siamese, Oriental Shorthairs, and related breeds should be educated about asthma symptoms and the importance of prompt treatment when respiratory signs develop. Early intervention with appropriate therapy can help prevent disease progression and airway remodeling.

Brachycephalic breeds including Persians, Himalayans, and Exotic Shorthairs present unique challenges for inhaled medication administration. Their shortened facial structure and flat nose conformation can make it difficult to achieve a proper seal with standard aerosol chamber face masks. Specialized mask sizing or designs may be needed for these cats. Additionally, brachycephalic cats may have complex respiratory conditions related to their anatomy that contribute to breathing difficulties beyond simple asthma. Thorough evaluation is important to ensure inhaled corticosteroid therapy is appropriate for the specific respiratory issues present. These breeds may also show more stress during mask placement, requiring extra patience during conditioning.

Breeds with predispositions to metabolic conditions warrant consideration during fluticasone therapy planning. Burmese cats have increased diabetes prevalence, and while inhaled fluticasone has minimal systemic effects, awareness of this predisposition is prudent. Any cat with existing diabetes receiving inhaled corticosteroids should have glucose levels monitored, though effects are typically much less significant than with oral steroids. Body size varies considerably among breeds, with larger cats like Maine Coons requiring no specific dose adjustment for inhaled therapy since doses are based on actuations rather than body weight. Age-related factors apply across all breeds, with geriatric cats often having concurrent conditions requiring consideration.

Several other inhaled corticosteroids are available as alternatives to fluticasone for feline respiratory disease. Budesonide and beclomethasone represent the main alternatives, each with slightly different pharmacokinetic properties and potencies. Cats that do not respond adequately to fluticasone or experience problematic local side effects may benefit from trying an alternative inhaled corticosteroid. The choice among these medications often depends on availability, cost, and individual patient response. Fluticasone remains the most commonly prescribed inhaled corticosteroid for cats due to extensive veterinary experience and the availability of multiple dosage strengths.

Bronchodilator medications are frequently used alongside inhaled fluticasone for comprehensive asthma management. Albuterol, delivered via metered-dose inhaler through an aerosol chamber, provides rapid bronchodilation for acute symptoms and serves as a rescue medication. The combination of inhaled corticosteroid for maintenance anti-inflammatory therapy and inhaled bronchodilator for rescue treatment mirrors established human asthma management protocols. Oral bronchodilators including terbutaline and theophylline offer alternative or additional bronchodilation, particularly for cats requiring rescue medication in injectable form for emergency use. The veterinarian determines the optimal combination of medications based on disease severity and individual patient needs.

Systemic corticosteroids, particularly oral prednisolone, represent an alternative approach for cats that cannot tolerate inhaled therapy due to inability to accept the aerosol chamber or other factors. While effective for controlling airway inflammation, systemic steroids produce significant side effects with long-term use, including increased thirst, urination, and appetite, weight gain, diabetes risk, and immune suppression. For cats that can tolerate inhaled administration, fluticasone offers superior long-term safety. Some cats may receive both inhaled fluticasone and short courses of oral steroids during severe disease flares, with the goal of using inhaled therapy alone for maintenance. Environmental management, including air purification and allergen reduction, provides complementary support for respiratory health.